Reports that the Food and Drug Administration (FDA) has issued a proposed regulation describing a new procedure for accelerated approval of a drug or biologic agent based on its effect on a surrogate end point indicating effectiveness of the product. Drugs and biological products used in the treatment of serious or life -threatening illnesses; More.